| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8221110 | International Journal of Radiation Oncology*Biology*Physics | 2013 | 9 Pages |
Abstract
The incidence of HT3+ depends on type of chemotherapy received. Patients receiving P-IMRT ± 5FU have better bone marrow tolerance than those receiving irradiation concurrent with either Cis or MMC. Treatment with MMC has a lower TD50 and more steeply rising normal tissue complication probability curve compared with treatment with Cis. Dose tolerance of PBM and the LSS subsite may be lower for patients treated with MMC compared with Cis.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Jose G. MD, MS, Gary PhD, Margaret M. BS, Eric M. BS, Steven L. MD, Daniel S. MD, PhD, Elizabeth A. MD, Albert C. MD, PhD, Daniel T. MD,